The effect of prion reduction in solvent/detergent-treated plasma on haemostatic variables

Vox Sanguinis

Volumn 99, Issue 3, 2010, Pages 232-238

  Lawrie, A S ^a   Green, L ^a   Canciani, M T ^b   MacKie, I J ^a   Peyvandi, F ^a,b   Scully, M A ^a   MacHin, S J ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

Author keywords

endogenous thrombin potential; fresh frozen plasma; Octaplas ; OctaplasLG ; prion reduction; S D plasma; thrombin generation test

Indexed keywords

ANTITHROMBIN; BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 11; BLOOD CLOTTING FACTOR 12; BLOOD CLOTTING FACTOR 13; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 9; D DIMER; DETERGENT; PRION PROTEIN; PROCOAGULANT; PROTEIN C; PROTEIN S; PROTEINASE INHIBITOR; PROTHROMBIN; SOLVENT; THROMBIN ANTITHROMBIN COMPLEX; VON WILLEBRAND FACTOR; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

AFFINITY CHROMATOGRAPHY; ARTICLE; BLOOD CLOTTING PARAMETERS; HEMOSTASIS; HUMAN; PLASMA; PRION; PRIORITY JOURNAL; RISK REDUCTION; ROTATIONAL THROMBOELASTOMETRY; THROMBIN TIME; THROMBOELASTOGRAPHY;

BLOOD PROTEINS; CHROMATOGRAPHY, AFFINITY; HEMOSTATICS; HUMANS; PLASMA; PRIONS;

EID: 77956636516     PISSN: 00429007     EISSN: 14230410     Source Type: Journal    
DOI: 10.1111/j.1423-0410.2010.01346.x     Document Type: Article

References (37)

1. O'Shaughnessy DF, Atterbury C, Bolton MP, Murphy M, Thomas D, Yates S, Williamson LM: Guidelines for the use of fresh-frozen plasma, cryoprecipitate and cryosupernatant. Br J Haematol 2004 126 (1 11 28
2. Stainsby D, MacLennan S, Thomas D, Isaac J, Hamilton PJ: Guidelines on the management of massive blood loss. Br J Haematol 2006 135 (5 634 641
3. Segal JB, Dzik WH: Paucity of studies to support that abnormal coagulation test results predict bleeding in the setting of invasive procedures: an evidence-based review. Transfusion 2005 45 (9 1413 1425
4. Department of Health, Dr Denise O'Shaughnessy (Senior Medical Advisor - Blood Policy): Availability of imported fresh frozen plasma in England and North Wales. http://www.dh.gov.uk/dr-consum-dh/groups/dh-digitalassets/@dh/@en/ documents/digitalasset/dh-4127680pdf2006 ; [21 February 2010]
5. United Kingdom Blood Transfusion Services: Guidelines for the Blood Transfusion Services in the United Kingdom, 7th edn. The Stationery Office, Norwich, UK. 2005
6. Heger A, Romisch J, Svae TE: A biochemical comparison of a pharmaceutically licensed coagulation active plasma (Octaplas) with a universally applicable development product (Uniplas) and single-donor FFPs subjected to methylene-blue dye and white-light treatment. Transfus Apher Sci 2006 35 (3 223 233
7. Heger A, Romisch J, Svae TE: Stability of solvent/detergent-treated plasma and single-donor fresh-frozen plasma during 48 h after thawing. Transfus Apher Sci 2005 33 (3 257 267
8. Health Protection Agency: Variant CJD and plasma products. http://www.hpa.org.uk/webw/HPAweb&HPAwebStandard/HPAweb-C/1195733818681?p= 1225960597236 2009 ; [21 February 2010]
9. Ward HJ, MacKenzie JM, Llewelyn CA, Knight RS, Hewitt PE, Connor N, Molesworth A, Will RG: Variant Creutzfeldt-Jakob disease and exposure to fractionated plasma products. Vox Sang 2009 97 (3 207 210
10. Cardigan R, Sutherland J, Garwood M, Krailadsiri P, Seghatchian J, Beard M, Beckman N, Williamson LM: The effect of leucocyte depletion on the quality of fresh-frozen plasma. Br J Haematol 2001 114 (1 233 240
11. Krailadsiri P, Seghatchian J, Macgregor I, Drummond O, Perrin R, Spring F, Prescott R, Williamson L, Prowse C, Anstee D, Turner M: The effects of leukodepletion on the generation and removal of microvesicles and prion protein in blood components. Transfusion 2006 46 (3 407 417
12. Neisser-Svae A, Bailey A, Gregori L, Heger A, Jordan S, Behizad M, Reichl H, Romisch J, Svae TE: Prion removal effect of a specific affinity ligand introduced into the manufacturing process of the pharmaceutical quality solvent/detergent (S/D)-treated plasma OctaplasLG. Vox Sang 2009 97 (3 226 233
13. European Pharmacopoeia Commission - Council of Europe European Department for the Quality of Medicines: Human plasma (pooled and treated for virus inactivation). European Pharmacopoeia 6 3 2009; 1646:4168-4170
14. Heger A, Svae TE, Neisser-Svae A, Jordan S, Behizad M, Romisch J: Biochemical quality of the pharmaceutically licensed plasma OctaplasLG after implementation of a novel prion protein (PrPSc) removal technology and reduction of the solvent/detergent (S/D) process time. Vox Sang 2009 97 (3 219 225
15. Lawrie AS, Harrison P, Cardigan RA, Mackie IJ: The characterisation and impact of microparticles on haemostasis within fresh-frozen plasma. Vox Sang 2008 95: 197 204
16. Lawrie AS, Cardigan RA, Williamson LM, Machin SJ, Mackie IJ: The dynamics of clot formation in fresh-frozen plasma. Vox Sang 2008 94: 306 314
17. Lawrie AS, Albanyan A, Cardigan RA, Mackie IJ, Harrison P: Microparticle sizing by dynamic light scattering in fresh frozen plasma. Vox Sang 2009 96: 206 212
18. Yarranton H, Lawrie AS, Mackie IJ, Pinkoski L, Corash L, Machin SJ: Coagulation factor levels in cryosupernatant prepared from plasma treated with amotosalen hydrochloride (S-59) and ultraviolet A light. Transfusion 2005 45 (9 1453 1458
19. Kremer Hovinga JA, Mottini M, Lammle B: Measurement of ADAMTS-13 activity in plasma by the FRETS-VWF73 assay: comparison with other assay methods. J Thromb Haemost 2006 4 (5 1146 1148
20. Budde U, Schneppenheim R, Plendl H, Dent J, Ruggeri ZM, Zimmerman TS: Luminographic detection of von Willebrand factor multimers in agarose gels and on nitrocellulose membranes. Thromb Haemost 1990 63 (2 312 315
21. Luddington RJ: Thrombelastography/thromboelastometry. Clin Lab Haematol 2005 27 (2 81 90
22. Kitchen S, Jennings I, Woods TA, Preston FE: Wide variability in the sensitivity of APTT reagents for monitoring of heparin dosage. J Clin Pathol 1996 49 (1 10 14
23. Hemker HC, Giesen P, al Dieri R, Regnault V, de Smedt E, Wagenvoord R, Lecompte T, Beguin S: Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Thromb 2003 33 (1 4 15
24. Gill JC, Endres-Brooks J, Bauer PJ, Marks WJ Jr. , Montgomery RR: The effect of ABO blood group on the diagnosis of von Willebrand disease. Blood 1987 69 (6 1691 1695
25. Jeanne M, Piquet Y, Ivanovic Z, Vezon G, Salmi LR: Variations of factor VIII:C plasma levels with respect to the blood group ABO. Transfus Med 2004 14 (2 187 188
26. McCallum CJ, Peake IR, Newcombe RG, Bloom AL: Factor VIII levels and blood group antigens. Thromb Haemost 1983 50 (3 757
27. O'Donnell J, Laffan MA: The relationship between ABO histo-blood group, factor VIII and von Willebrand factor. Transfus Med 2001 11 (4 343 351
28. Shima M, Fujimura Y, Nishiyama T, Tsujiuchi T, Narita N, Matsui T, Titani K, Katayama M, Yamamoto F, Yoshioka A: ABO blood group genotype and plasma von Willebrand factor in normal individuals. Vox Sang 1995 68 (4 236 240
29. Bihm DJ, Ettinger A, Buytaert-Hoefen KA, Hendrix BK, Maldonado-Codina G, Rock G, Giclas PC, Goodrich RP: Characterization of plasma protein activity in riboflavin and UV light-treated fresh frozen plasma during 2 years of storage at -30 degrees C. Vox Sang 2010 98 (2 108 115
30. Irsch J, Pinkoski L, Corash L, Lin L: INTERCEPT plasma: comparability with conventional fresh-frozen plasma based on coagulation function - an in vitro analysis. Vox Sang 2010 98 (1 47 55
31. Aznar JA, Bonanad S, Montoro JM, Hurtado C, Cid AR, Soler MA, De Miguel A: Influence of methylene blue photoinactivation treatment on coagulation factors from fresh frozen plasma, cryoprecipitates and cryosupernatants. Vox Sang 2000 79 (3 156 160
32. Scully M, Longair I, Flynn M, Berryman J, Machin SJ: Cryosupernatant and solvent detergent fresh-frozen plasma (Octaplas) usage at a single centre in acute thrombotic thrombocytopenic purpura. Vox Sang 2007 93 (2 154 158
33. Chekrizova V, Murphy WG: Solvent-detergent plasma: use in neonatal patients, in adult and paediatric patients with liver disease and in obstetric and gynaecological emergencies. Transfus Med 2006 16 (2 85 91
34. Baglin T, Gray E, Greaves M, Hunt BJ, Keeling D, Machin S, Mackie I, Makris M, Nokes T, Perry D, Tait RC, Walker I, Watson H: Clinical guidelines for testing for heritable thrombophilia. Br J Haematol 2010 149 (2 209 220
35. Alvarez-Larran A, Del RJ, Ramirez C, Albo C, Pena F, Campos A, Cid J, Muncunill J, Sastre JL, Sanz C, Pereira A: Methylene blue-photoinactivated plasma vs. fresh-frozen plasma as replacement fluid for plasma exchange in thrombotic thrombocytopenic purpura. Vox Sang 2004 86 (4 246 251
36. Williamson LM, Cardigan R, Prowse CV: Methylene blue-treated fresh-frozen plasma: what is its contribution to blood safety? Transfusion 2003 43 (9 1322 1329
37. Pock K, Heger A, Janisch S, Svae TE, Romisch J: Thrombin generation capacity is impaired in methylene-blue treated plasma compared to normal levels in single-donor fresh-frozen plasma, a licensed solvent/detergent-treated plasma (Octaplas) and a development product (Uniplas). Transfus Apher Sci 2007 37 (3 223 231